Premium
Establishing guidelines for pharmacotherapy trials in bulimia nervosa and anorexia nervosa
Author(s) -
Mitchell James E.,
Tareen Basir,
Sheehan William,
Agras Stewart,
Brewerton Timothy D.,
Crow Scott,
Devlin Michael,
Eckert Elke,
Halmi Katherine,
Herzog David,
Marcus Marsha,
Powers Pauline,
Stunkard Albert,
Walsh B. Timothy
Publication year - 2000
Publication title -
international journal of eating disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.785
H-Index - 138
eISSN - 1098-108X
pISSN - 0276-3478
DOI - 10.1002/(sici)1098-108x(200007)28:1<1::aid-eat1>3.0.co;2-h
Subject(s) - anorexia nervosa , bulimia nervosa , pharmacotherapy , psychiatry , psychology , eating disorders , psychotherapist , medicine , clinical psychology
Objective This paper addresses the lack of a standard protocol for pharmacotherapy trials for patients with bulimia nervosa (BN) and anorexia nervosa (AN). Method Twenty‐two surveys were sent to established researchers in the field of eating disorders to elicit their opinions regarding medication trials, including baseline laboratory tests, the optimal length/frequency of medication management sessions, and the information that should or should not be included in these sessions. Results Sixteen of 22 researchers completed and returned the survey. Their answers are the basis of the data presented. Discussion We propose a battery of screening laboratory tests for both conditions. We suggest 30–45‐min initial medication management sessions in both AN and BN trials with 15‐min follow‐ups to be held weekly for AN subjects, and weekly for 2 weeks, then biweekly for 2 weeks, then monthly, for BN subjects. We also recommend that published trials should include explicit details of medication management. © 2000 John Wiley & Sons, Inc. Int J Eat Disord 28: 1–7, 2000.